EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Comprehensive Analysis of Epoxide Hydrolase 2 ( EPHX2 ) in Pan‐Cancer

Weiquan Hu, Xiaoli Ding, Xiangsheng Wu, Xuxiang Xi, Jing Xu, Shengyun Dai, Jing Chen, Suping Hu, Qinfei Zhao iD, Fangfang Chen

Cancer Reports · 2025

DOI: 10.1002/cnr2.70188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Weiquan Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Joint Surgery, Ganzhou People's Hospital, Ganzhou, Jiangxi, China. Hauptthemen laut MEDLINE: Epoxide Hydrolases, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Clinical Diagnosis and Treatment New Technology Project, Guiding Science and Technology Plan Project of Ganzhou, General Program of the Jiangxi Administration of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Epoxide hydrolase 2 (EPHX2) regulates lipid signaling across various metabolites by encoding soluble epoxide hydrolase. However, its mechanisms and implications in human malignancies remain unknown. This research aimed to detail the prognostic landscape of EPHX2 in pan‐cancer and explore its potential relationship with immune infiltration in the tumor microenvironment.

Methods

Herein, multiple bioinformatics tools were used to comprehensively evaluate the expression, diagnostic, and prognostic significance of EPHX2 and its roles in the tumor immune microenvironment in human cancers. The underlying EPHX2‐associated signaling pathways in cancers were investigated by gene set variation analysis (GSVA). TIDE, GDSC, and CTRP databases were applied to predict the response of EPHX2 to immunotherapy and sensitivity to small molecule drugs. Furthermore, EPHX2 expression was also validated by qPCR experiments in various cancer cell lines.

Results

Overall results revealed significant down‐regulation of EPHX2 mRNA expression in most tumors. Despite its high predictive significance across cancers, EPHX2 played a protective or detrimental effect in distinct types of cancers. EPHX2 proved to be a valuable diagnostic biomarker in a range of tumor types, particularly in kidney renal clear cell carcinoma, cervical squamous cell carcinoma, and endocervical adenocarcinoma. Genetic alterations of EPHX2 in 33 tumors were also investigated. EPHX2 expression was significantly linked to immune cell infiltrations (particularly tumor‐associated macrophages), tumor mutation burden, microsatellite instability, immune modulators, and immunotherapeutic biomarkers. Single‐cell sequencing and GSVA highlighted the relevance of EPHX2 in regulating various cancer‐related biological processes, including cell cycle and apoptosis. In this view, targeting EPHX2‐dependent signaling could be a promising therapeutic strategy for tumor immunotherapy.

Conclusion

EPHX2 may serve as a potential molecular biomarker for diagnosis and prognosis in pan‐cancer and could become a novel therapeutic target for various cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epoxide HydrolasesNeoplasmsBiomarkers, TumorHumansTumor MicroenvironmentPrognosisGene Expression Regulation, NeoplasticComputational BiologyCell Line, Tumor

Stichwörter der Autor:innen

EPHX2immune checkpoint blockade (ICB)immune infiltrationimmunotherapypan‐cancerprognosis

Substanzen

Epoxide HydrolasesEPHX2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Joint Surgery, Ganzhou People's Hospital, Ganzhou, Jiangxi, China.
  • Department of Laboratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
  • Department of Orthopaedic Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.
  • National Institutes for Food and Drug Control, Beijing, China.
  • Department of Emergency, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
  • The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.

ORCID-Profile: Qinfei Zhao

Förderung

  • Clinical Diagnosis and Treatment New Technology Project
  • Guiding Science and Technology Plan Project of Ganzhou
  • General Program of the Jiangxi Administration of Traditional Chinese Medicine
  • City-Level Scientific Research Project of Ganzhou Municipal Health Commission
  • First Affiliated Hospital of Gannan Medical University's faculty-level project
  • Science and Technology Plan of Health Commission of Jiangxi Province
  • Jiangxi Traditional Chinese Medicine Science and Technology Program
  • National Natural Science Foundation of China

Zitieren

APA

Hu, W., Ding, X., Wu, X., Xi, X., Xu, J., Dai, S., Chen, J., Hu, S., Zhao, Q., & Chen, F. (2025). A Comprehensive Analysis of Epoxide Hydrolase 2 ( EPHX2 ) in Pan‐Cancer. Cancer Reports. https://doi.org/10.1002/cnr2.70188

Vancouver

Hu W, Ding X, Wu X, Xi X, Xu J, Dai S, et al. A Comprehensive Analysis of Epoxide Hydrolase 2 ( EPHX2 ) in Pan‐Cancer. Cancer Reports. 2025. doi:10.1002/cnr2.70188

BibTeX
@article{Hu2025,
  author = {Hu, Weiquan and Ding, Xiaoli and Wu, Xiangsheng and Xi, Xuxiang and Xu, Jing and Dai, Shengyun and Chen, Jing and Hu, Suping and Zhao, Qinfei and Chen, Fangfang},
  title = {A Comprehensive Analysis of Epoxide Hydrolase 2 ( EPHX2 ) in Pan‐Cancer},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70188}
}
Kostenlos starten →